AEZS vs. INAB, APRE, OKUR, SNTI, MIRA, LPCN, BCAB, MEIP, MRKR, and CARM
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include IN8bio (INAB), Aprea Therapeutics (APRE), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), MIRA Pharmaceuticals (MIRA), Lipocine (LPCN), BioAtla (BCAB), MEI Pharma (MEIP), Marker Therapeutics (MRKR), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical products" industry.
Aeterna Zentaris vs.
IN8bio (NASDAQ:INAB) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
Aeterna Zentaris has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
IN8bio has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
IN8bio presently has a consensus price target of $7.75, indicating a potential upside of 2,754.51%. Given IN8bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe IN8bio is more favorable than Aeterna Zentaris.
Aeterna Zentaris received 394 more outperform votes than IN8bio when rated by MarketBeat users. However, 73.53% of users gave IN8bio an outperform vote while only 59.18% of users gave Aeterna Zentaris an outperform vote.
92.1% of IN8bio shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 15.5% of IN8bio shares are held by company insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, IN8bio and IN8bio both had 2 articles in the media. IN8bio's average media sentiment score of 0.13 beat Aeterna Zentaris' score of 0.00 indicating that IN8bio is being referred to more favorably in the media.
IN8bio has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat IN8bio's return on equity.
Summary
IN8bio beats Aeterna Zentaris on 9 of the 15 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
This page (NASDAQ:AEZS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free AEZS Stock Alerts